Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Autoinflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-1R1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-1R1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IL-1R1 Products |
| Gene Delivery | IL-1R1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL-1R1 Products |
| Benchmark Ab | Anti-IL-1R1 (Sequence of Reference Monoclonal) Recombinant positive control. |
View IL-1R1 Products |
| Validator | IL-1R1 siRNA Set For knockdown verification. |
View IL-1R1 Products |
| Related Target A | IL-1A Primary pro-inflammatory ligand blocked by IL-1R1 antagonism. |
View IL-1A Products |
| Related Target B | IL-1RAP Essential co-receptor required for IL-1 signaling complex formation. |
View IL-1RAP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog IL-1R1 ECD proteins available with >95% purity and strictly theoretical MW. |
| Receptor family counter-screening | IL-1R2 (decoy) and IL-1RAP homolog panels rigorously controlled and sequence verified by mass spec. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks in cell-based assays. |
Live IL-1R1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-1R1 therapeutics is intensifying, with major players shifting focus from traditional recombinant receptor antagonists to long-acting monoclonal antibodies and bispecific formulations. As first-generation therapies reach the clinic for rheumatoid arthritis and autoinflammatory syndromes, the next wave of R&D is targeting extended half-life formulations for Sub-Q administration, broader dermatological indications (such as hidradenitis suppurativa), and synergy with IL-1RAP targeting to combat severe localized and systemic inflammation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Amgen, Novartis | Rheumatoid Arthritis, Dermatology | Binding Affinity (Need high-purity, natively glycosylated ECD-Fc) |
| Recombinant Antagonist / Trap | Sobi (Anakinra), Regeneron | CAPS, Gout, Pericarditis | Ligand Blocking (Need structurally pristine IL-1A/B and IL-1R1) |
| Bispecific (IL-1R1 x IL-1RAP) | Emerging Biotechs | Refractory Autoimmune | Heterodimer Validation (Need distinct cross-reactive control Abs) |
| Small Molecule | Various early-stage | Systemic Inflammation | Selectivity Assay (Need precisely sequence-verified WT/mutant ECDs) |